Getting the Right Diagnosis

Getting an accurate diagnosis for Familial Partial Lipodystrophy Type 3 (FPLD3) is often a journey of ruling out more common conditions. Because the fat loss can be subtle, many patients are initially told they simply have “ordinary” Type 2 Diabetes or Polycystic Ovary Syndrome (PCOS) ^[1][2]. However, FPLD3 is a distinct genetic condition that requires a specific diagnostic approach.

Why FPLD3 is Often Misidentified

The biggest hurdle to a diagnosis is that FPLD3 “hides” behind common metabolic problems ^[1].

• The PCOS Mimic: Many women with FPLD3 are first diagnosed with PCOS because they have irregular periods, excess hair growth, and insulin resistance ^[3]. However, in FPLD3, these symptoms are driven by the body’s inability to store fat safely, which is not the case in standard PCOS ^[4].
• The Diabetes Mimic: Doctors may assume a patient has standard Type 2 Diabetes, especially if they are not traditionally “obese” ^[5]. A major clue for FPLD3 is having severe metabolic disease—like extremely high triglycerides or requiring high doses of insulin—at a relatively low body weight ^[1][6].

The Diagnostic Process: Integrating Phenotype and Genetics

Diagnosis is not based on a single test, but rather an integration of a compatible clinical phenotype (your physical appearance), your metabolic lab results, and genetic testing ^[6].

Your care team will look for a specific pattern: fat loss in the arms, legs, and hips, while fat on the trunk (stomach area) is often preserved ^[7][2].

• Physical Exam and Skinfolds: Clinicians may use calipers to measure the thickness of fat under the skin at specific sites like the thighs, calves, and triceps ^[8]. In FPLD3, these measurements are typically lower than average for your age and sex ^[9].
• DXA Scan and MRI: A DXA scan can provide a “fat shadow” to calculate the percentage of fat in your limbs versus your trunk ^[10]. A whole-body MRI is the most detailed way to visualize fat atrophy and assess hepatic steatosis (fatty liver) ^[5][11]. While helpful for phenotyping, these scans are not strictly required for every patient and do not have universal diagnostic cutoffs.

The Role of Genetic Testing

Genetic testing helps confirm a suspected clinical diagnosis and identifies the specific molecular subtype ^[9].

• Gene Panels: Doctors often order a multigene panel ^[12]. This checks several lipodystrophy-related genes at once (including PPARG) to ensure the correct subtype is identified ^[1].
• Pathogenic Variants vs. VUS: Finding a “pathogenic” (disease-causing) variant in the PPARG gene strongly supports the diagnosis ^[3]. However, sometimes a test returns a “Variant of Uncertain Significance” (VUS). A VUS means a genetic change was found, but science hasn’t yet proven if it causes disease ^[13]. A VUS cannot be used to establish a diagnosis on its own, and a negative panel does not completely rule out lipodystrophy.

Genetics and Your Family

PPARG-related FPLD3 is generally inherited in an autosomal dominant pattern with variable expression ^[1]. This means that if you carry a heterozygous pathogenic variant, each of your children has a 50% chance of inheriting the same variant. However, a family member who inherits it might have a milder or later-onset phenotype than you do.

Action Steps for Families:

1. Genetic Counseling: Always review your genetic test results with a certified genetics professional who can explain the inheritance pattern and family planning risks.
2. Cascade Testing: If a known pathogenic variant is identified, your first-degree relatives (parents, siblings, children) can be offered targeted “cascade testing” for that specific variant ^[14].